Drugs / IMELCIMENT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05291546 | Apr 2022 → Apr 2024 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMELCIMENT | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068125 ↗ |
| Known as | REGN9035 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05291546 ↗ |
| Modality | Protein / enzyme biologic | “an Anti-REGN5381 Antibody and Reversal Agent” NCT05291546 ↗ |
| Route | Intravenous | “Single dose administered by IV infusion on day 1” NCT05291546 ↗ |